$OKLO

Oklo Inc.

Oklo develops fast fission power plants called Aurora powerhouses, designed to produce electricity and heat for customers including data centers, military and government facilities, factories, industrial users, remote communities, campuses and utilities. It plans to design, build, own and operate the powerhouses, which are designed to use fresh, recycled or down-blended nuclear fuel. Oklo’s primary business model is to sell energy directly to customers through power purchase agreements rather than sell reactor designs. Oklo is also developing nuclear fuel recycling and fuel fabrication capabilities, including facilities intended to turn used nuclear fuel into fuel for its reactors and those of others. Through its wholly owned subsidiary Atomic Alchemy, it is developing radioisotope production for medical, research, energy, industrial, defense and artificial intelligence applications. Oklo is headquartered in Santa Clara, California.

22
5
6
—
$2.6M
Narayanadas Vivek
77%
See all $OKLO insider activity →
Med

Oklo Soars 23% on a Narrower Loss and Forging Capacity for 27 Reactors It Hasn’t Sold Yet

Oklo (OKLO) shares rose 22.7% after reporting a narrower Q3 loss of $0.22 per share, beating estimates. The company secured manufacturing capacity for 27 Aurora modules, though no binding power contract is signed. Revenue was $1.86M, up from estimates. NuScale Power (SMR) also gained 16.3%. Oklo's enterprise value is $1.9B, with analysts expecting $6.3B in free cash flow outflows by 2030.

Oklo (OKLO) Q3 2026 Earnings Call Transcript

Oklo (OKLO) reported Q3 2026 progress, highlighting advancements in reactor construction, fuel infrastructure, and isotope production. The company secured DOE authorization for projects, including Aurora-Idaho, and benefits from new NRC rules. DOE's Nuclear Lifecycle Innovation Campus initiative aligns with Oklo's strategy, offering potential funding and infrastructure support.

OKLO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 33 news stories mentioning OKLO (Oklo Inc.). Coverage has skewed bullish: 22 bullish, 5 neutral, and 6 bearish.

Recent OKLO coverage spans insider activity, financial news and earnings.

In the last 30 days, OKLO insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($2.6M). The most active reporter was Narayanadas Vivek, General Counsel & Secretary, with 3 filings. 77% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving OKLO

AlphAI scores every news story that mentions OKLO with an AI model for sentiment and relevance, and aggregates insider trades from Oklo Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OKLO

Score

Oklo Soars 23% on a Narrower Loss and Forging Capacity for 27 Reactors It Hasn’t Sold Yet

Oklo (OKLO) shares rose 22.7% after reporting a narrower Q3 loss of $0.22 per share, beating estimates. The company secured manufacturing capacity for 27 Aurora modules, though no binding power contract is signed. Revenue was $1.86M, up from estimates. NuScale Power (SMR) also gained 16.3%. Oklo's enterprise value is $1.9B, with analysts expecting $6.3B in free cash flow outflows by 2030.

Oklo (OKLO) Q3 2026 Earnings Call Transcript

Oklo (OKLO) reported Q3 2026 progress, highlighting advancements in reactor construction, fuel infrastructure, and isotope production. The company secured DOE authorization for projects, including Aurora-Idaho, and benefits from new NRC rules. DOE's Nuclear Lifecycle Innovation Campus initiative aligns with Oklo's strategy, offering potential funding and infrastructure support.

Nuclear company plans $70M purchase at LEAP District for medical isotope production

Oklo Inc.'s subsidiary, Bigfoot Metals Development LLC, plans to buy 440 acres in Indiana's LEAP District for $70.4M to produce medical isotopes. The deal, signed with the Indiana Economic Development Corp, includes potential uses like nuclear power and energy storage. Oklo, a publicly traded nuclear tech company, is also developing reactors and isotopes for medicine and research.

Related tickers